Skip to main content

06-11-2018 | Immunotherapy | Editorial | Article

Immunotherapy for patients with metastatic NSCLC harboring an EGFR mutation

Charu Aggarwal
Management of EGFR-mutant non-small-cell lung cancer has been dominated by targeted therapies, but it is less clear where immunotherapy will fit into the treatment paradigm. Dr Charu Aggarwal (University of Pennsylvania, USA) explores the current place of immunotherapy in treating this disease.

Please log in to get access to this content

Related topics

More on this topic

image credits